determination: rvd vs high-dose melphalan conditioning with autohsct in ndmm
Published 2 years ago • 212 plays • Length 5:30Download video MP4
Download video MP3
Similar videos
-
2:22
high-dose melphalan as a preparative regimen for autohsct in hl and nhl
-
1:41
results from determination: rvd with or without asct
-
2:49
genomic changes induced by high-dose melphalan in myeloma
-
2:16
the impact of high-dose melphalan on myeloma-related mutations & risk level
-
5:46
determination: results & implications in clinical practice
-
4:06
high-dose melphalan increases the mutational load in myeloma cells at relapse
-
1:59
mutational burden at relapse following exposure to high dose melphalan in multiple myeloma
-
2:34
the mutagenic impact of melphalan in myeloma
-
4:01
hair regrowth after chemo
-
3:05
updates from the determination trial: rvd vs. autosct in patients with multiple myeloma
-
17:10
optimal test utilization for bone marrow staging evaluations
-
2:55
the addition of bortezomib to melphalan-based conditioning in multiple myeloma
-
1:21
vrd induction, mel200-conditioned autohsct and lenalidomide maintenance in multiple myeloma
-
2:05
alnuctamab: improved route of administration and optimized dose level & dosing schedule
-
0:36
race trials new zantrene drug for extramedullary acute myeloid leukaemia (emd aml) – animation
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
1:49
evaluating erythroid precursors in patients with lr-mds to predict response to esas
-
3:22
anchor: melphalan flufenamide in r/r myeloma
-
1:50
molecular characteristics of extramedullary myeloma
-
1:00
proof of principle to progress treatments
-
1:15
an insight into response criteria for waldenström’s macroglobulinemia
-
2:47
using artificial intelligence to estimate overall mortality and non-relapse mortality after allosct